Skip to content

HIV & AIDS Health Center

New Study May Aid Search for AIDS Vaccine

Research Could Lead to New Strategies for the Development of an Effective HIV Vaccine
Font Size
A
A
A
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Aug. 17, 2011 -- In the spring of 1997, then-president Bill Clinton called for an effective AIDS vaccine within a decade. Fourteen years and billions of research dollars later, a vaccine to prevent HIV infection remains an elusive goal.

International efforts to develop a useful HIV vaccine have proven disappointing, with failed clinical trials and dashed hopes. But a new study may represent an important break in the search.

Researchers with the Scripps Howard Research Institute and the International AIDS Vaccine Initiative (IAVI) have identified 17 new antibodies with broad activity against HIV.

Some of the antibodies are 10 times more potent than any that had previously been identified, and the hope is that they will turn out to be new targets for potential HIV vaccines.

The research appears today in the online issue of the journal Nature.

New Paths for AIDS Vaccine

Vaccines that target viruses work by training the immune system to recognize and kill invading viruses. They do this by exposing the body to a harmless form of the targeted virus.

The reason it has been so hard to develop a vaccine against HIV is that the virus mutates far more often than most other disease-causing pathogens.

“Unlike other viruses, like measles or polio, you can’t just make a weakened form because HIV is crafty enough that if you weaken it the virus figures out a way to return to its virulent form,” IAVI Chief Science Officer Wayne Koff, PhD, tells WebMD.

Although earlier research has identified the outer protein coating of the HIV virus as a major target of antibodies that inhibit infection, Koff says investigators had not previously identified the specific vulnerable sites on the protein to target with a vaccine.

Within a few years of infection most people who are HIV positive do not produce virus-targeting antibodies, but a minority of patients do.

By studying serum samples from HIV-infected people around the world, the researchers identified a select few who not only produced these antibodies, but who produced remarkably effective ones that neutralized a broad range of HIV subtypes at very low concentrations.

Today on WebMD

misconception
How much do you know?
contemplative man
What to do now.
 
research
Should you be tested?
HIV under microscope
What does it mean?
 
HIV AIDS Screening
Slideshow
man opening condom wrapper
Quiz
 
HIV AIDS Treatment
Feature
Discrimination Stigma
Feature
 
Treatment Side Effects
Feature
grilled chicken and vegetables
Article
 
obese man standing on scale
Article
cold sore
Article
 

WebMD Special Sections